Mechanisms of sunitinib malate (SU) resistance in gastrointestinal stromal tumors (GISTs)
Michael C. Heinrich(VA Portland Health Care System), Jonathan A. Fletcher(Harvard University), Rachel Donsky(Brigham and Women's Hospital), Amy Harlow(Brigham and Women's Hospital), Bernadette Liegl(Brigham and Women's Hospital), Monica M. Bertagnolli(National Institutes of Health), Chandrajit P. Raut(Dana-Farber Cancer Institute), G. D. Demetri(Brigham and Women's Hospital), Christopher D.�M. Fletcher(Brigham and Women's Hospital), Christopher L. Corless(Oregon Health & Science University)
Cited by 19
Related Papers
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
|Journal of the National Comprehensive Cancer Network|2010|1.2k
Celecoxib for the Prevention of Sporadic Colorectal Adenomas
|New England Journal of Medicine|2006|1k